Eldelumab (anti-IP-10) induction therapy for ulcerative colitis: a randomised; placebo-controlled; phase 2b study

dc.contributor.author	Sandborn, WJ
dc.contributor.author	Colombel, JF
dc.contributor.author	Ghosh, S
dc.contributor.author	Sands, BE
dc.contributor.author	Dryden, G
dc.contributor.author	Hebuterne, X
dc.contributor.author	Leong, RW
dc.contributor.author	Bressler, B
dc.contributor.author	Ullman, T
dc.contributor.author	Lakatos, Péter László
dc.contributor.author	Reinisch, W
dc.contributor.author	Xu, LA
dc.contributor.author	Luo, A
dc.date.accessioned	2019-10-04T13:32:35Z
dc.date.available	2019-10-04T13:32:35Z
dc.date.issued	2016
dc.identifier	84966378462
dc.identifier.citation	journalVolume=10;journalIssueNumber=4;journalTitle=JOURNAL OF CROHNS & COLITIS;pagerange=418-428;journalAbbreviatedTitle=J CROHNS COLITIS;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/7350
dc.identifier.uri	doi:10.1093/ecco-jcc/jjv224
dc.format.extent	418-428
dc.relation.ispartof	urn:issn: 1873-9946 1876-4479
dc.title	Eldelumab (anti-IP-10) induction therapy for ulcerative colitis: a randomised; placebo-controlled; phase 2b study
dc.type	Journal Article
dc.date.updated	2019-07-30T10:43:36Z
dc.language.rfc3066	en
dc.rights.holder	NULL
dc.identifier.mtmt	2984607
dc.identifier.wos	000374262300007
dc.identifier.pubmed	26721935
dc.contributor.department	SE/AOK/K/I. Sz. Belgyógyászati Klinika
dc.contributor.institution	Semmelweis Egyetem